Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
MAIN-CAV
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
- NCT05092958 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Deep
We haven't built an HCP commentary report on MAIN-CAV (avelumab and cabozantinib s-malate in Advanced Bladder Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MAIN-CAV so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 37 | |
| YouTube | 6 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma; Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8
- Interventions
- Avelumab; Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm A (avelumab) · Active comparator
- Arm B (avelumab, cabozantinib) · Experimental
- Enrollment
- 654 (estimated)
- Primary outcomes
- Overall survival (OS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 3, 2022
- Primary completion
- Jul 15, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05092958 · updated Oct 26, 2026